J.P. Morgan Downgrades Sanofi-Aventis (SNY) to Neutral
More News related to SNY
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009
- Sanofi-aventis Video Q&A: CEO Chris Viehbacher Comments on Q3 '09 Earning and Outlook
More News related to Downgrades
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
J.P. Morgan downgrades Sanofi-Aventis (NYSE: SNY) from Overweight to Neutral.
To see more analyst ratings on SNY Click Here.
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
Related Categories
DowngradesStocks Mentioned
-0.11Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
